Evaluation of Transforming Growth Factor-β1 and Interleukin-35 Serum Levels in Patients with Placenta Accreta

Objective: Placenta accreta is a pregnancy-related disorder with extreme trophoblast invasion and the adherence of the placenta to the uterine wall. This study aimed to investigate the serum level of transforming growth factor-beta 1 (TGF-beta 1) and interleukin (IL)-35 in patients with placenta accreta. Methods: Thirty-one women with placenta accreta and 57 healthy pregnant women were enrolled. The serum levels of TGF-beta 1 and IL-35 were measured using the enzyme-linked immunosorbent assay method. Results: The serum levels of both TGF-beta and IL-35 were significantly higher in the placenta accreta group compared with the group of healthy women (1082.48 pg/mL vs 497.33 pg/mL and 4541.14 pg/mL vs 1306.04 pg/mL; P<.001, respectively). Moreover, the level of TGF-beta 1 positively correlated with the IL-35 level but other factors such as age, gestations, live births, and abortions did not correlate with IL-35 and TGF-beta 1 levels. Conclusion: The serum levels of IL-35 and TGF-beta 1 may contribute to the pathogenesis of placenta accreta and could be considered as potential targets in clinical and diagnostic approaches.

Automated summary

The serum levels of TGF-beta 1 and IL-35 were significantly elevated in patients with placenta accreta compared to healthy pregnant women, indicating a potential role in the pathogenesis of the disorder and suggesting them as potential targets for clinical and diagnostic approaches.